



HEA-205

Food and Drug Administration
Rockville MD 20857

6 3 5 6 '03 EST 14 19:44

OCT 06 2003

Taro Pharmaceuticals U.S.A.
Attention: Avraham Yacobi, Ph.D.
Five Skyline Drive
Hawthorne, NY 10532

Docket No. 03P-0307/CP1

Dear Dr. Yacobi:

This is in response to your petition filed on July 7, 2003, requesting permission to file an Abbreviated New Drug Application (ANDA) for the following drug product: Warfarin Sodium Tablets, 1.5 mg. The listed drug product to which you refer in your petition is Coumadin® (Warfarin Sodium) Tablets, 2 mg, approved under NDA 09-218 held by Bristol Myers Squibb.

Your request involves a change in strength from that of the listed drug product (i.e., from 2 mg to 1.5 mg). The change you request is the type of change that is authorized under the Federal Food, Drug, and Cosmetic Act (Act).

We have reviewed your petition under Section 505(j)(2)(C) of the Act and have determined that it is approved. This letter represents the Food and Drug Administration's (FDA) determination that an ANDA may be submitted for the above-referenced drug product.

Under Section 505(j)(2)(C)(i) of the Act, the FDA must approve a petition seeking a strength that differs from the strength of the listed drug product unless it finds that investigations must be conducted to show the safety and effectiveness of the differing strength.

The FDA finds that the change in strength for the specific proposed drug product does not pose questions of safety or effectiveness because the uses, dose, dosage form and route of administration of the proposed drug product are the same as that of the listed drug product. The approved labeling for the listed drug indicates that doses of warfarin sodium must be individualized and adjusted for each patient based upon the patient's PT/INR response to the drug and that certain patient populations require lower initiation and maintenance doses of warfarin sodium. The FDA concludes, therefore, that investigations are not necessary in this instance. In addition, if shown to meet bioavailability requirements, the proposed drug product can be expected to have the same therapeutic effect as the listed reference drug product.

The approval of this petition to allow an ANDA to be submitted for the above-referenced drug product does not mean that the FDA has determined that an ANDA will be approved for the drug product. The determination of whether an ANDA will be approved is not made until the ANDA itself is submitted and reviewed by the FDA.

03P-0307

PAV 1


Docket No. 03P-0307/CP1
Warfarin Sodium Tablets, 1.5 mg
Taro Pharmaceuticals, U.S.A

To permit review of your ANDA submission, you must submit all information required under Sections 505(j)(2)(A) and (B) of the Act. To be approved, the drug product will, among other things, be required to meet current bioavailability requirements under Section 505(j)(2)(A)(iv) of the Act. We suggest that you submit your protocol for the drug product to the Office of Generic Drugs, Division of Bioequivalence, prior to the submission of your ANDA. During the review of your application, the FDA may require the submission of additional information.

The listed drug product to which you refer in your ANDA must be the drug product upon which you based this petition. In addition, you should refer in your ANDA to the appropriate petition docket number cited above, and include a copy of this letter in the ANDA submission. Please note that once an application is approved for a drug product that is the same as the subject of this petition, that drug product will be a listed drug. Thereafter, the petition may not be utilized as the basis for submission of an ANDA.

A copy of this letter approving your petition will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely yours,



Gary J. Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

Docket No. 03P-0307/CP1
Warfarin Sodium Tablets, 1.5 mg
Taro Pharmaceuticals, U.S.A

Concurrence:



Gary Buehler
Director
Office of Generic Drugs

Date: 10/6/03

cc: Petition File
HFA-305/Dockets Management Branch
HFD-1/CDER/Chron. File
HFD-600/G. Buehler/C. Parise Petition File
HFD-613/Labeling Review Branch
HFD-615/Regulatory Support Staff/M.Shimer
HFD-650/Division of Bioequivalence
GCF-1/K. Dettelbach/L. Whipkey
RD by M.Shimer, 10/2/03
Edited by C.Parise, 10/3/03
v:\petition\letters\2003\03P-0307.doc
FT by
Petition Letter!